Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Hepatitis C Virus
100%
Drug Users
70%
Amsterdam
57%
Injecting Drug Users
45%
Intensive Care Unit
39%
Influenza
35%
Netherlands
30%
Risk Factors
28%
Virus-specific T Cells
26%
Seroconversion
24%
Hepatitis C Virus Infection
23%
Seroconverter
20%
HIV-infected Patients
19%
AIDS/HIV
19%
COVID-19
18%
Invasive Aspergillosis
18%
Harm Reduction
18%
Virus-specific
16%
T Cell Response
15%
Hepatitis C Virus RNA
13%
Viral Clearance
12%
Non-structural Protein
12%
CD4+ T
12%
Clinical Outcomes
12%
Chronic Hepatitis C
12%
Highly Active Antiretroviral Therapy (HAART)
11%
Virus Incidence
11%
Acute Hepatitis C Virus Infection
11%
Risk Behavior
11%
Non-associated
11%
High-risk Population
10%
Intra-abdominal Candidiasis
10%
Intensive Care Unit Mortality
10%
Incidence Rate
10%
Sustained Virological Response
10%
Influenza Season
10%
Europe
10%
CD4+ T Cell Response
10%
Incidence Risk
10%
Female Sex
10%
ICU Patients
9%
Infectious Diseases
9%
95% Confidence Interval
9%
Methadone
9%
ST152
9%
Hepatopulmonary Syndrome
9%
Immune Reconstitution
9%
Longitudinal Analysis
9%
Toxoplasmic Encephalitis
9%
Ongoing Risk
9%
Immunology and Microbiology
Hepatitis C Virus
88%
Infection
43%
Infectious Disease
42%
Hepatitis C
39%
T Cell
30%
Human Immunodeficiency Virus
28%
Seroconversion
23%
Viral Clearance
21%
T-Helper Cell
21%
Influenza
18%
Ribonucleic Acid
14%
Hepatitis B Virus
10%
Hepatitis B
10%
Synergism
9%
Superinfection
9%
Peginterferon Alpha
9%
Human Immunodeficiency Virus 1
9%
COVID-19
9%
Ribavirin
9%
Staphylococcus Aureus
9%
High Risk Population
9%
Hepatitis
9%
Hepatitis B Core Antibody
9%
CD4
6%
Mortality Rate
5%
Comorbidity
5%
Memory T Cell
5%
Medicine and Dentistry
Intensive Care Unit
45%
Influenza
27%
Invasive Aspergillosis
18%
Lung Aspergillosis
12%
Cohort Analysis
11%
Candidiasis
10%
Pneumonia
9%
Infectious Disease
9%
Human Immunodeficiency Virus
9%
Immune Reconstitution Inflammatory Syndrome
9%
Retrospective Cohort Study
9%
Hepatopulmonary Syndrome
9%
Encephalitis
9%
Systemic Candidiasis
9%
Klebsiella Pneumoniae Infection
9%
COVID-19
9%
Klebsiella pneumoniae
9%
Glycemic
9%
Sexual Transmission
9%
HIV/AIDS
9%
Infection
7%
Right-to-Left Shunt
6%
Liver Disease
6%
Public Health
6%